BAFF- and APRIL-targeted therapy in systemic autoimmune diseases

被引：53

作者：

Nakayamada S. ^{[1
]}

Tanaka Y. ^{[1
]}

机构：

[1] First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahata-nishi, Kitakyushu

来源：

Inflammation and Regeneration | / 36卷 / 1期

关键词：

APRIL; Autoimmune diseases; B cells; BAFF; Tfh cells;

D O I：

10.1186/s41232-016-0015-4

中图分类号：

学科分类号：

摘要：

B cells play a pivotal role in autoimmunity not only by producing pathogenic autoantibodies but also by modulating immune responses via the production of cytokines and chemokines. The B cell-activating factor/a proliferation-inducing ligand (BAFF/APRIL) system promotes B cell survival and differentiation and thus plays a prominent role in the pathogenesis of autoimmune diseases. Currently, BAFF and APRIL inhibitors are in clinical trials for systemic lupus erythematosus with significant efficacy. However, several studies have demonstrated the efficacy of the BAFF/APRIL blockade which showed considerable variability in the response to B cell-targeted therapy. This may indicate substantial heterogeneity in the pathogenesis of autoimmune diseases. Therefore, objective markers that can predict the effect of BAFF/APRIL-blocking agents could be valuable to the precision medicine linked clinically and to cost-effective therapy. © 2016 Nakayamada and Tanaka.

引用

共 67 条

[1]

Arbuckle M.R., McClain M.T., Rubertone M.V., Et al., Development of autoantibodies before the clinical onset of systemic lupus erythematosus, N Engl J Med., 349, pp. 1526-1533, (2003)

[2]

Liu Z., Davidson A., Taming lupus-a new understanding of pathogenesis is leading to clinical advances, Nat Med., 18, pp. 871-882, (2012)

[3]

Tanaka Y., Yamamoto K., Takeuchi T., Et al., A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus, Mod Rheumatol, 17, pp. 191-197, (2007)

[4]

Merrill J.T., Neuwelt C.M., Wallace D.J., Et al., Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial, Arthritis Rheum., 62, pp. 222-233, (2010)

[5]

Rovin B.H., Furie R., Latinis K., Et al., Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study, Arthritis Rheum, 64, pp. 1215-1226, (2012)

[6]

Nagafuchi H., Atsumi T., Hatta K., Et al., Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis, Mod Rheumatol., 25, pp. 603-608, (2015)

[7]

Nakayamada S., Saito K., Nakano K., Tanaka Y., Activation signal transduction by beta1 integrin in T cells from patients with systemic lupus erythematosus, Arthritis Rheum., 56, pp. 1559-1568, (2007)

[8]

Desai-Mehta A., Lu L., Ramsey-Goldman R., Datta S.K., Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production, J Clin Invest., 97, pp. 2063-2073, (1996)

[9]

Grammer A.C., Slota R., Fischer R., Et al., Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions, J Clin Invest., 112, pp. 1506-1520, (2003)

[10]

Crispin J.C., Kyttaris V., Juang Y.T., Tsokos G.C., Systemic lupus erythematosus: New molecular targets, Ann Rheum Dis., 66, pp. iii65-iii69, (2007)

← 1 2 3 4 5 6 7 →